ImmunityBio Announces Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio has announced a phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells collected from healthy donors undergoing apheresis. The study will enroll up to 10 healthy subjects and will involve two apheresis collections. Subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous injection 4 to 5 days prior to the second apheresis collection.
September 19, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio's announcement of a phase 1 study for N-803 could potentially impact the company's stock. The study's success could lead to increased investor confidence and a potential rise in stock price.
The announcement of a new phase 1 study indicates progress in ImmunityBio's product pipeline. If the study yields positive results, it could increase investor confidence in the company's ability to bring new products to market, potentially leading to a rise in stock price.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 100